Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1        Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL   
Page 1 of 42  
Evaluation  of the Performance of CONTOUR  NEXT¬Æ and CONTOUR  
PLUS ELITE¬Æ Blood Glucose Monitoring Systems  in Neonates  using 
Capi[INVESTIGATOR_559202] /Clinical Investigation Plan:   
GCA -PRO -2021 -003-01  
 Amendment 1 :  14 October 2022  
 
  
Sponsor:               Ascensia Diabetes  Care  
                            [ADDRESS_734638]  
                            Valhalla, NY  [ZIP_CODE]  
 
 
Maria Teresa Viggiani , MS, CCRA  
Clinical Trial Manager , 
Clinical Affairs   Date   Scott Pardo, PhD, PStat¬Æ 
Deputy Director,  Statistics and 
Data Management  
 
 
 
Global Clinical Affairs  
 
 
  Date  
Rosanna Cirio, MA 
Manager, Clinical Affairs  
  Date   James Venosky, NPDP  
Sr. Program Manager  
 
 
  
  Date  
Rimma Shaginian , MD, MPH  
Medical Lead  - Emerging Markets  
 
  Date   Shahrir Alam  
Regulatory Affairs Product 
Manager   Date  
 
 
 
 
  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1        Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL   
Page [ADDRESS_734639] (IRB) , the 
Ascensia Diabetes Care  study manager must approve any changes to the protocol.  I also agree to 
protect the rights, safety, dignity, and well -being of the subjects.  
 
Principal Investigator  (PI):     Dennis Dietzen , PhD 
Site:                                         St. Louis Children‚Äôs Hospi[INVESTIGATOR_307] , Washington University  
Address:                                  1 Children‚Äôs Place  
                                                             St. Louis , MO  [ZIP_CODE]   
 
_____________________________ ____    ______ _______ ______ _____ _______ _     ____________________  
                     PI [INVESTIGATOR_559203]  (ADC) . 
 
  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1        Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL   
Page 3 of 42 Table of Contents   
 
Abbreviations ................................ ................................ ................................ ................................  5 
1.0 Identification of the Protocol/ Clinical Investigation Plan (CIP)  ................................ ...............  [ADDRESS_734640] Information  ................................ ................................ ................................ .............  7 
3.0 Synopsis of the Clinical Study  ................................ ................................ ................................  8 
4.0 Identification and description of the investigational device  ................................ ...................  9 
5.0 Justification for the Design of the Clinical Study ................................ ................................ .... 10 
6.0 Risks and benefits of the investigational device and clinical investigation  .............................  11 
7.0 Objectives and Hypotheses  ................................ ................................ ................................ .. 12 
8.0 Clinical Study Design  ................................ ................................ ................................ ............  12 
9.0 Investigational device(s) and comparator(s)  ................................ ................................ .........  13 
10.0  Subjects  ................................ ................................ ................................ ...........................  14 
11.0  Procedures  ................................ ................................ ................................ .......................  15 
12.0  Monitoring Plan  ................................ ................................ ................................ ...............  20 
13.0  Statistical Plan ................................ ................................ ................................ ..................  20 
14.0  Data Management  ................................ ................................ ................................ ...........  24 
15.0  Amendments to the Protocol ................................ ................................ ............................  24 
16.0  Deviations from the clinical protocol  ................................ ................................ ................  26 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1        Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL   
Page 4 of 42 17.0  Device Accountability  ................................ ................................ ................................ .......  26 
18.0  Regulatory  ................................ ................................ ................................ .......................  27 
19.0  Statements of compliance  ................................ ................................ ................................  28 
20.0  Informed Consent Process  ................................ ................................ ................................  28 
21.0  Adverse events and adverse device effects  ................................ ................................ .......  29 
22.0  Handling and Reporting of Device Deficiencies  ................................ ................................ .. 31 
23.0  Vulnerable population  ................................ ................................ ................................ ...... 32 
24.0  Suspension/Premature termination and Subject Withdrawal Criteria  ................................  32 
25.0  Results Handling  ................................ ................................ ................................ ..............  32 
26.0  Publication policy  ................................ ................................ ................................ .............  32 
27.0  Administration  ................................ ................................ ................................ .................  33 
28.0  Bibliography  ................................ ................................ ................................ .....................  33 
Appendix A - Instructions for Cleaning and Disinfecting Meters  ................................ .....................  34 
Appendix B - Instructions for Processing of Blood for the glucose analyzer  ................................ .... 35 
Appendix C - Instructions for Tracking Accuracy and Precision of the Laboratory Glucose Analyzer  36 
Appendix D - Instructions for Hematocrit Sample Preparation and Testing  ................................ .... 38 
Attachment 1 - CONTOUR NEXT User Guide  ................................ ................................ ..................  39 
Attachment 2 - CONTOUR PLUS ELITE User Guide  ................................ ................................ .........  41 
 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1        Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL   
Page [ADDRESS_734641]  
BG Blood  Glucose  
BGMS  Blood Glucose Monitoring  System  
CIP Clinical Investigation Plan (Protocol)  
CRF  Case Report  Form  
EDC  Electronic Data Capture  
GCP  Good Clinical Practice  
HCP  Health Care Professional  
ICF Informed Consent  Form  
IRB Institutional Review Board  
LAR  Legally Authorized Representative  
NICU Neonatal I ntensive Care  Unit 
PI [INVESTIGATOR_559204] /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 6 of 42 1.0 Identification of the  Protoc ol/ Clinical Investigation Plan (CIP)  
1.1 Title of the clinical investigation :  Evaluation of the Performance of CONTOUR  
NEXT¬Æ and CONTOUR  PLUS ELITE¬Æ Blood Glucose Monitoring Systems in Neonates  
using Capi[INVESTIGATOR_559205]  
1.2 Protocol Number:  GCA -PRO -2021 -003-01 
1.3 Date:   Octo ber 1 4, 2022  
1.4 Revision Status  
 
Date  Revision History  
30Jun2022                    Initial Release  version  
14Oct2022  1. Amendment 1  
Sections 3.0, 8.2, and 10.1.1: Changed ‚Äú up to 150 subjects may be enrolled to 
obtain the required number of samples ‚Äù to ‚Äúup to 200 subjects  may be enrolled to 
obtain the required number of samples .‚Äù  
Section 13.1.2:   Changed ‚Äúmeter results will be 2*120 = 240 ‚Äù to ‚Äúmeter results 
will be at least 2*120 = 240 .‚Äù  
Section 13.10: Added ‚Äúor valid‚Äù to the following statements: ‚ÄúSamples with 
no associated or valid hematocrit value.‚Äù  ‚ÄúSamples with no associated or valid 
Cobas 6000 value.‚Äù  
Appendix D: Added ‚ÄúEnsure the tube setting on the Hemata Stat II‚Ñ¢ is set to 
0.5 mm ID (inner diameter).‚Äù  
 
 
 
 
  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734642] Information  
2.1 Sponsor :   Ascensia Diabe tes Care  
                                [ADDRESS_734643]:  
 
Maria Teresa Viggiani  
Phone (Office): [ADDRESS_734644]: 914 -417-9310  
E-mail: [EMAIL_10656]                    OR Rosanna Cirio  
Phone (Office): [ADDRESS_734645]: 914 -343-5736  
E-mail: [EMAIL_10657]  
 
     
 
2.2 Principal Investigator  (PI):     Dennis Dietzen, PhD  
2.2.[ADDRESS_734646] details :  St. Louis Children‚Äôs Hospi[INVESTIGATOR_307]  
     1 Children‚Äôs Place  
     St. Louis, MO  [ZIP_CODE]  
     [PHONE_11630]  
      [EMAIL_10658]  
2.2.2 Professional position, roles, responsibilities and qualifications :  
             Professor of Pathology & Immunology, and Pediatrics, Washington University  
                         Medical Director, Laboratory Services, St. Louis Children‚Äôs Hospi[INVESTIGATOR_559206], Laboratory Services, Children‚Äôs Specialty Care Center, St. Louis  
                         PhD, Biochemistry and Molecular Biology, Indiana University  School of Medicine  
 
2.3 Name [CONTACT_559242] :  Site address is the same as in 2.2.1 . 
                        Business address of the site:  Washington University  
     One Brookings Drive  
     Campus Box [ADDRESS_734647]. Louis, MO  [ZIP_CODE]  
 
2.4 Name(s) and address(es) of other institutions involved :   Not Applicable   
2.5 Description of study financing and the agreement between the sponsor/site.  
Separate document: Clinical Trial Agreement between Ascensia Diabetes Care and Washington 
University, S t. Louis.   
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 8 of 42 3.0 Synopsis of the Clinical Study  
Design Type:   Open Label, prospective, single  arm study  
Investigational 
Devices:  CONTOUR  NEXT  ¬Æ Blood Glucose Monitoring System (BGMS)  
CONTOUR  PLUS ELITE¬Æ Blood Glucose Monitoring System  
Trial objective  The purpose of th is study is to extend the intended use of two BGMSs to 
include testing of neonatal blood by [CONTACT_559225] a clinical 
setting for the quantitative measurement of glucose levels in neonates.  
This trial will evaluate  the performance of both the CONTOUR  NEXT  
BGMS  and CONTOUR  PLUS ELITE  BGMS using blood from  neonates 
within a hospi[INVESTIGATOR_111494] , e.g. routine/newborn nurseries, Special Care 
Nurseries, Neonatal Intensive Care Unit  (NICU).  The investigational 
BGMS s will be  tested  by a P oint-of-Care operator using  residual heel -stick 
capi[INVESTIGATOR_559207].  
Reference Analyzer  Cobas¬Æ 6000  
Sample size : A total of 120 blood  samples  tested in duplicate with N=[ADDRESS_734648] 
5 capi[INVESTIGATOR_559208].  
Inclusion and 
Exclusion 
criteria : Inclusion Criteria  
‚Ä¢ Residual capi[INVESTIGATOR_1396] (heel -stick) blood samples collected from neonates (less 
than 28 days of age) after birth as part of prescribed testing.  
‚Ä¢ Sample  blood  volume  must  be sufficient  to complete  investigational  testing  
in addition  to routine prescribed clinical laboratory  testing.  
Exclusion  Criteria  
‚Ä¢ Samples from subjects  who are ‚â• 28 days of age . 
‚Ä¢ Samples from subjects who have previously been enrolled into this study.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 9 of 42 Objectives 
and 
Endpoints : The primary objective of the study is to evaluate the performance of CONTOUR  
NEXT  and CONTOUR  PLUS ELITE  BGMSs with residual neonatal  blood 
samples . The performance of the BGMSs will be analyzed according to the 
following objectives:  
Primary Objective:  
‚Ä¢ At least 95% of all blood glucose results shall fall within ¬±12.5%  of reference 
values (laboratory method) for glucose concentration ‚â•100 mg/dL  (5.55 
mmol/L ) and within ¬±12 mg/dL  (¬±0.67 mmol/L)  at glucose concentrations 
<100 mg/dL  (5.55 mmol/L) . 
‚Ä¢ At least 98% of values sh all be within ¬±20% of reference values (laboratory 
method) for glucose concentration ‚â•75 mg/dL  (4.16 mmol/L)  and within ¬±15 
mg/dL (¬±0.83 mmol/L) at glucose concentrations < 75 mg/dL  (4.16 mmol/L) .  
Number of study sites  [ADDRESS_734649]‚Äôs participation is not applicable because the study uses 
residual samples.  
4.0 Identification and description of the investigational device  
4.1 Name [CONTACT_559243]:  
‚Ä¢ CONTOUR  NEXT  blood glucose monitoring system ( Meter, CONTOUR  NEXT  Test 
Strips , Control solutions)   
‚Ä¢ CONTOUR  PLUS ELITE  blood glucose monitoring system ( Meter, CONTOUR  PLUS  
Test Strips, Control solutions)   
4.2 Intended purpose  of investigational devices  
4.2.1 The CONTOUR  NEXT  and CONTOUR  PLUS ELITE  blood glucose monitoring 
systems ( BGMS ) are investigational BGMS s comprised of  the blood glucose meter, 
the compatible test strips, and control solutions . They  are automated   systems 
intended for the quantitative   measurement of glucose in  fresh capi[INVESTIGATOR_559209] , arterial blood, and venous blood.  Its use in this 
trial is for the quantitative measurement of glucose levels in neonates from fresh 
capi[INVESTIGATOR_559210].  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 10 of 42 4.2.2 The  system is intended to be used for self -testing  by [CONTACT_559226] -patient testing by  [CONTACT_559227] s (HCP) to monitor  the 
effectiveness of diabetes control .   
4.2.3 The BGMS can only be used for monitoring blood glucose levels and is not for 
diagnosis or screening of diabetes. The system is intended for in vitro  diagnostic use 
only.  
4.3 Ascensia Diabetes Care (ADC) is the m anufacturer of the device . 
4.[ADDRESS_734650]  between the devices and the patients is required since all testing will be 
performed on blood sampled from a tube.  
4.7 The technical and functional features of the investigational devices , CONTOUR  NEXT  and 
CONTOUR  PLUS ELITE  BGMSs , can be found in the User Guides (UG) in  Attachment s 
1 and 2.   
4.8 The instructions for use for the devices are found in the UGs ( Attachment s 1 and 2).  
4.9 Training and experience required for use of the device is Good Clinical Practice ( GCP ) 
training, and laboratory experience.  The study staff will be provided specific device 
training as part of the Site Initiation Visit (SIV) by [CONTACT_456] .  
5.[ADDRESS_734651] BGMS that are currently used are initia lly developed for monitoring 
blood glucose levels in adult patients with diabetes. Neonatal blood differs from adult blood in two 
major aspects ‚Äîit has lower concentrations of blood glucose and a wider range of hematocrit levels  
(Adamkin 2011; BAPM 2017; Ha rris et al 2012; Lucas et al 1988; Movalia and Ogino 2006; 
Nuntnarumit et al 2011 ; Roth -Kleiner et al 2010; Rozance 2006) .  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734652], e.g. 
routine/newborn nurseries, S pecial Care Nurserie s (SCN) , Neonatal Intensive Care Units ( NICU ). 
The BGMS will be used by a POC operator in a clinical setting using residual heel-stick capi[INVESTIGATOR_559211] . The residual blood no 
longer needed for clinical purposes will be used for this study.  
6.[ADDRESS_734653] (neonate) for donation of residual blood samples for this 
study except to contribute to a study that provides information on the performance of two BGMS s 
when measuring glucose in capi[INVESTIGATOR_559212] a clinical setting . Subjects will not 
receive compensation . 
There are no anticipated adverse device effects.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 12 of 42 7.0 Objectives and Hypotheses  
The primary objective of the study is to evaluate the performance of CONTOUR  NEXT  and 
CONTOUR  PLUS ELITE  BGMSs with residual heel-stick capi[INVESTIGATOR_559213], 
i.e. babies who are less than 28 days old . The performance of the BGMS  will be analyzed according 
to the following objectives :  
7.1 Primary Objective : The accuracy criteria below are taken from CLSI. Point -of-Care Blood 
Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline ‚Äì Third Edition . 
CLSI document POCT12 -A3. Wayne, PA: Clinical and Laboratory Standards Institute; 
2013.   
7.1.[ADDRESS_734654] 95% of all blood glucose results shall fall within ¬±12 .5% of reference values 
(laboratory method) for glucose concentration ‚â•100 mg/dL  (5.55 mmol/L)  and 
within ¬±12 mg/dL  (¬±0.67 mmol/L)  at glucose concentrations <100 mg/dL  (5.55 
mmol/L) . 
Note: Sat isfying Criterion  7.1.1  would also satisfy the ISO [ZIP_CODE] :2013  criteria of 
obtaining the ¬±15% of reference values (laboratory method) for glucose 
concentration ‚â•100 mg/dL (5.55 mmol/L)  and within ¬±15 mg/dL  (¬±0.83 mmol/L)  at 
glucose concentrations <100 mg/dL  (5.55 mmol/L).  
7.1.[ADDRESS_734655] 98% of values sh all be within ¬±20% of reference values (laboratory method) 
for glucose concentration ‚â•75 mg/dL  (4.16 mmol/L)  and within ¬±15 mg/dL  (¬±0.83 
mmol/L)  at glucose concentrations < 75 mg/dL  (4.16 mmol/L) . 
7.2 Other Objectives:  
‚Ä¢ Evaluate the performance of both BGMSs for neonates who are <[ADDRESS_734656] 
hematocrit results.  
‚Ä¢ Evaluate the performance of both BGMSs with blood samples from babies in the NICU .  
‚Ä¢ Compute differences between BGMS and laboratory blood glucose measurements and plot 
them against bilirubin  results , for those subjects where bilirubin measurements were recorded 
(when available) . 
8.0 Clinical Study Design  
8.1 This is an open label , prospective, single arm study .   The results of the study devices will 
be compared to the laboratory analyzer results from the same blood sample . 
8.2 For each BGMS, 120 evaluable samples (N=240 evalu able results  due to  duplicate testing ) 
are required . Therefore at least 120 subjects will be enrolled.  Up to 200 subjects may be 
enrolled to obtain the required number of samples.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 13 of 42 8.3 Randomization : 
8.3.1 Since two BGM Ss will be tested in the study, the order of testing the study devices 
will be randomized.   
8.3.2 Three strip lots (per BGMS) will be tested, with each sample tested with one lot.  
The strip lots will be randomized.  
8.4 The results from these two BGMS s will not be compared to each other.  
8.5 The study design follows  CLSI - POCT12 -A3:2013 and ISO [ZIP_CODE]:2019(E)  to ensure it is 
scientifically robust and valid.  
8.6 Subjects  with non -evaluable data will be replaced as needed to obtain N=120 samples, and 
N= 240 results (duplicate results) for each BGMS.  
9.0 Investigational device(s) and comparator(s)   
9.1 Materials and  Methods  
9.1.1 Resources  Supplied  by [CONTACT_10670]  - Staffing  
‚Ä¢ Principal Investigator / and , if applicable,  Sub-Investigators  
‚Ä¢ HCP to collect blood samples  
‚Ä¢ Laboratory professionals to perform meter testing, hematocrit, and laboratory analyzer  
testing  
9.1.2 Resources Supplied by [CONTACT_10670] - Other  
‚Ä¢ Hospi[INVESTIGATOR_370354]/or Central IRB approval of the protocol . 
‚Ä¢ Facility with adequate laboratory resources for conducting all tests ( including blood 
glucose laboratory analyzer, hematocrit measurement instrument) . 
‚Ä¢ Facility with adequate neonatal  population for at least 120  study -appropriate samples  
within  the desired course of the trial.  
‚Ä¢ Cobas¬Æ 6000 ([COMPANY_002] Diagnostics Corp., Indianapolis, IN) Laboratory Analyzer , to 
measure glucose in plasma .  
‚Ä¢ Print -outs of the Cobas 6000  results  for Quality Control ( QC) checks  during  study  days. 
9.1.3 Resources  Supplied by [CONTACT_127007]  - Materials  
‚Ä¢ Protocol and sample Case Report Form s (CRF)  
‚Ä¢ CONTOUR   NEXT¬Æ meters  
‚Ä¢ CONTOUR   NEXT¬Æ strips  (3 lots)  with inserts  
‚Ä¢ CONTOUR   NEXT¬Æ UGs  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 14 of 42 ‚Ä¢ CONTOUR   PLUS ELITE¬Æ meters  
‚Ä¢ CONTOUR  PLUS¬Æ strips  (3 lots) with inserts  
‚Ä¢ CONTOUR   PLUS ELITE¬Æ UGs  
‚Ä¢ CONTOUR  NEXT¬Æ and CONTOUR  PLUS¬Æ Low ,  Normal  and High  Control 
solution s with inserts  
‚Ä¢ Hematocrit instrument and testing supplies  
‚Ä¢ Thermometer/hygrometers for measuring environmental conditions at the 
meter testing location , if needed . The site may use its calibrated measuring 
devices with approval of ADC.  
‚Ä¢ Disinfectant  (see Appendix A for procedure and detail ) 
‚Ä¢ Serum  controls  for the laboratory glucose  analyzer  
‚Ä¢ Atomic clock (s) 
9.[ADDRESS_734657] Bluetooth¬Æ ON. 
9.[ADDRESS_734658]  120 blood samples with evaluable results ( N=240) are required 
for this study . Up to [ADDRESS_734659] of neonates from hospi[INVESTIGATOR_173967] (e.g. 
routine/newborn nurseries, SCN , NICU) of the clinical  investigational site.  
10.1.[ADDRESS_734660] demographics , including age and gender . 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 15 of 42 10.1.7  Unused residual blood samples collected for study testing procedures will be 
discarded according to hospi[INVESTIGATOR_559214] (O ccupational 
Safety and Health Administration ) procedures.  
10.2 Inclusion Criteria  
10.2.1  Residual capi[INVESTIGATOR_1396] (heel -stick) blood samples from neonate s (less than 28 days 
of age) after birth as part of prescribed testing.  
10.2.[ADDRESS_734661] be sufficient to complete investigational testing in 
addition to routine prescribed clinical laboratory  testing.  
10.3 Exclusion  Criteria  
10.3.1  Samples from subjects  who are ‚â• [ADDRESS_734662] previously been enrolled into this study.   
10.4 Study Duration  
10.4.1  The t otal expected duration to complete  the clinical investigation  is ~[ADDRESS_734663]'s participation  is not applicable  since there 
is no direct subject participation .  Only  residual blood sample s from subject s 
will be tested per the study procedures only on the day of sample collectio n. 
11.[ADDRESS_734664] the glucose concentration of residual capi[INVESTIGATOR_559215], collected (into a tube) from neonatal heel -sticks only,  using the CONTOUR  NEXT  and 
CONTOUR  PLUS ELITE  BGMSs. The investigational site will enroll neonates from hospi[INVESTIGATOR_559216] (e,g, routine/newborn nurseries, SCN, NICU). For subject safety and ethical reasons, only 
those neonates already scheduled to have blood samples obtained for prescribed testing (by [CONTACT_86677][INVESTIGATOR_33717]), will be enrolled into this study.   No neonate will have heel -stick blood collected 
solely for the purpose of this study.  
A minimum of 10 capi[INVESTIGATOR_559217] (from residual neonatal heel -stick) will be tested 
in duplicate on  both BGMSs. A sub -group of at least [ADDRESS_734665] 5 blood samples will be from  neonates 
in the NICU. These two sub -group s‚Äô samples are permitted to overlap.  
Up to  50uL of whole blood will be removed from the subject's sample tube , and will be used for 
completing a total of 4 tests using both BGMSs (two tests with CONTOUR  NEXT  BGMS and 
two tests with CONTOUR  PLUS ELITE  BGMS), and a hematocrit measurement . Each subject 
sample will be tested using both BGMS as per the randomization schedule. After completion of 
the BGMS testing, each meter will be cleaned and disinfected as per the procedures in Appendix 
A.    
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 16 of 42 The site staff will use their Laboratory Glucose Analyzer (approved by [CONTACT_1034]) for the 
laboratory assessment of blood glucose samples tested in duplicate  as part of prescribed testing  of 
the same sample . The laboratory duplicate results will be averaged . In cases where the prescribed 
test for the sample is a bilirubin analysis, the results of this test will be recorded as part of the study 
data.  
During the study, three test strip lots will be used for each BGMS. The test strip lots will be 
arbitrarily designated  as green, blue , or red to easily identify the bottles during the study. See Table 
[ADDRESS_734666] strip lots . The assignment will be made in a rotating order following the random 
order in which samples are  received.  For each sample, t he order of testing each of the two 
BGMSs will also be randomized.  
Table 1 .  Strip Lot Assignments Per Meter Type  
Meter System &  
Test Strips  Green Lot  Red Lot  Blue Lot  
CONTOUR  NEXT  Meter 
(CONTOUR  NEXT  Test Strips ) ~40 Samples  
~80 tests  
 ~40 Samples  
 ~80 tests  
 ~40 Samples  
~80 tests  
 
CONTOUR  PLUS ELITE  Meter 
(CONTOUR  PLUS Test  Strips ) ~40 Samples  
~80 tests  ~40 Samples    
~80 tests  ~40 Samples  
~80 tests  
 
11.2 Study Staff Training  
The site study staff will be given copi[INVESTIGATOR_559218] (UG). 
They will participate in a training session conducted by [CONTACT_559228].  The 
training will be documented, and t he following will be reviewed:  
11.2.1  Protocol & CRF s 
11.2.2  Meter Instructions for Use (UG)  
11.2.3  Meter control solution testing  
11.2.4  Error messages and troubleshooting  
11.2.5  GCP 
11.2.6  Practice using  the CONTOUR  NEXT  and CONTOUR  PLUS ELITE  BGMSs  
11.2.7  Practice preparing and reading hematocrit samples   
 
11.3 Meter Control Solution  Testing  
Control testing on the study BGMS will occur after they arrive at the site and before the trial 
starts.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 17 of 42 11.3.1  The site staff will equally distribute (approximately) the strip lots for control 
testing . 
11.3.2  The site staff will perform 3 control tests (one each of low, normal , and high) on 
each BGMS assigned for the study.   
11.3.[ADDRESS_734667] 
strip bottle.  
11.3.4  If results are out of range, troubleshooting will be performed (see UG) , and the test 
will be repeated for a total of up to 3 attempts.  
11.3.5  If the meter tests are out of range after troubleshooting is complete, the meter will be 
removed from the study, and the Ascensia Study Manager will be notified.  
Additionally, this will be documented on the ‚ÄòDevice Deficiency Reporting Form ‚Äô. 
11.4 Blood  Glucose  Testing  
11.4.1  No blood will be taken from study subjects solely for this study. Neonatal 
blood will be collected for prescribed testing and residual blood from the 
sample will be used for this study. Blood will be collected following HCP's 
orders by [CONTACT_41207]/phlebotomy staff using standard heel puncture techniques. 
All samples will be transported to the laboratory per standard practice and 
submitted for prescribed clinical testing. Samples will be collected according 
to hospi[INVESTIGATOR_559219] a tube 
containing anticoagulants (lithium heparin).  
11.4.[ADDRESS_734668] sufficient volume to complete 
the required investigational testing will not be used for the clinical trial.  
11.4.3  If sufficient volume is available, this is the time of enrollment.  N o more than 
the agreed amount (50 uL) of capi[INVESTIGATOR_559220] a hematocrit  measurement .  
11.4.4  The collected samples will be used within a maximum of 5 h of sample 
collection  time, and will be kept at room temperature (23 ¬± 5 ¬∞C) before 
evaluation . 
11.4.[ADDRESS_734669] digit will indicate the site ID followed by 
[CONTACT_559229]: X -001, X -002, X -003, and so 
on. 
11.4.6  Strip lot (color  code ) will be determined via a randomization schedule provided by 
[CONTACT_1034]. The testing order of the meter will also be based on a randomization 
schedule. Note that one CONTOUR  NEXT  and one CONTOUR  PLUS ELITE  
BGMS per subject will be used and the meters will be disinfected after use as per 
procedures listed in Appendix A . 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734670] strip (as assigned for the given 
BGMS) will be inserted into each of the 2 meters (same  color code strip lot for both 
meters).  
11.4.8  A drop of blood will be placed on a pi[INVESTIGATOR_559221] (or other non -absorbent 
material) and immediately tested with the first  a n d  s e c o n d  meter.  
11.4.[ADDRESS_734671] and second meter .  
11.4.11  A hematocrit measurement (%) will also be performed . (See Section 11.6.)  
11.4.12  The blood (from the same sample as used in meter testing) will be centrifuged within 
[ADDRESS_734672] , plasma samples may 
be refrigerated.  
11.5 Errors  
11.5.1  If the meter reports an error code during blood glucose testing, the instructions 
shown in the UG should be followed.  Re -testing is recommended (per the UG).  The 
reason for the repeated test will be documented in the comments section of the form. 
No more than a  total of [ADDRESS_734673] one hematocrit tube, but preferably t wo, will be filled with the residual 
whole blood and then centrifuged.   
11.6.2  The hematocrit will be measured from only one tube; the second tube will be 
collected as a backup in case the first tube is not measurable (i.e., tube spun out, 
broken tube, clay seal compromised, etc.).  Additional details regarding hematocrit 
measurements are found in Appendix D.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734674]/action  Description  
1 Sample prep  ‚ñ™ Ensure  collection of residual neonatal  sample in collection tube  containing 
anticogulant (lithium/heparin) . 
‚ñ™ Confirm sufficient blood volume to perform all testing  procedures .  
‚ñ™ If so, then aliquot up to  50 uL into microtube and cover.  
2 Testing prep Assign one CONTOUR  NEXT meter and one CONTOUR  PLUS  ELITE  
meter to the patient sample.   
‚ñ™ Follow the strip lot randomization (red, gree n, blue) and get the test strip 
bottle for the respective meter.  
‚ñ™ Get a pi[INVESTIGATOR_559222].  
‚ñ™ For steps [ADDRESS_734675]  1 ‚ñ™ Put a test strip into each meter.  
‚ñ™ Immediately place [ADDRESS_734676] results.  
‚ñ™ In case of error, may repeat 2 more times with a new blood drop.  
‚ñ™ Record time of successful meter test s.  
[ADDRESS_734677] 2 ‚ñ™ Replace test strips , and p lace new blood drop on parafilm to repeat Step 3 
for duplicate testing.  
5 Hematocrit  ‚ñ™ Using the blood from the same collection tube, fill up to 2 hematocrit tubes.  
‚ñ™ Perform hematocrit measurement, and r ecord result s. 
6 Centrifugation  ‚ñ™ Centrifuge blood, and record start time. ( The centrifugation start time must  
be within 10 min of meter tests).  
7 Laboratory 
tests* ‚ñ™ Perform blood glucose testing of plasma sample on laboratory analyzer  
(Cobas) in duplicate .   
‚ñ™ Record results . 
* Pre -study and on-study serum control testing on Cobas: See 11.[ADDRESS_734678] bilirubin data.   
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 20 of 42  
11.10  Temperature and Humidity Logs  
‚Ä¢ The study staff will measure the temperature /humidity in the meter testing area once during 
the day that meter testing occurs and record the results on the appropriate log form .  
‚Ä¢ Study staff will maintain a temperature log for the storage of investigational materials 
including the meters, test strips, controls, and serum controls.  
12.0 Monitoring Plan  
12.1 A monitoring plan will be completed by [CONTACT_127024]/designee prior to the study . 
12.[ADDRESS_734679] the SIV. The frequency of the number of 
monitoring visits by [CONTACT_559230](s) will be based on the monitoring plan 
and will include at least [ADDRESS_734680].  
13.0 Statistical Plan  
13.1 Sample  Size 
13.1.1  The sample size requirement is based on the primary objective, section 7.0. 
13.1.2  There will be a minimum of N = [ADDRESS_734681] 2*120 = 240.  
13.1.3  With a sample size of n = 240 results, there is approximately a 95% chance that at 
least  228  of those results (95% of 240) will be "accurate" (errors within either ¬±12 
mg/dL  (¬±0.67 mmol/L)  when the comparator result is < 100 mg/dL  (5.55 mmol/L) , 
or ¬±12.5% when the comparator result is ‚â• 100 mg/dL  (5.55 mmol/L ) if the  
evaluation (meter)  system has a 96.77% chance of yielding an "accurate"  result.  
13.1.4  Conversely, there is about a 95% chance of obtaining fewer than 228 "accurate" 
results if the system only has an approximately 92.03% chance of yielding an 
accurate result.  
13.1.5  Note that each glucose result obtained with the evaluation devices will be considered 
either 'accurate' or 'not accurate ‚Äô, where accuracy depends on the particular test 
criterion as described in section 7.0 of this protocol.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 21 of 42 13.2 Blood Glucose  Measurements  
Data analysis follows analyses and presentations described in CLSI. Point -of-Care Blood Glucose 
Testing in Acute and Chronic Care Facilities; Approved Guideline ‚Äì Third Edition . CLSI 
document POCT12 -A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.  
The unit conversion formula for blood glucose is the following:  
Xmmol/L = Ymg/dL / 18.016  
13.3 Bland -Altman  Plots  
Modified Bland -Altman plots (the difference between each evaluation device results and reference 
results plotted against reference results) will be constructed.  
13.[ADDRESS_734682] comparator results will be performed.  
If M represents the meter result, and C the comparator result, the linear model can be expressed as:  
ùë¥= ùú∑ùüé+ùú∑ùüèùë™+ùú∫ 
ùú∫~ùëµ(ùüé,ùíÑùíó‚àóùë™) 
The parameter cv is the coefficient of variation, which is assumed to be constant across the glucose 
range.  The weighting function will be:  
ùíò=ùë™‚àíùüê 
This weighting function is used to account for the constant cv nature of glucose measurement 
(Draper and Smith, 1998).  
13.5 Accuracy Analyses  
13.5.1  Two sets of metrics will be calculated:  
Relative (Percent) Difference (RD) for reference result  ‚â• threshold glucose:  
ùëπùë´ =ùë¥‚àíùë™
ùë™ùüèùüéùüé % 
where: M = strip/meter result and C = comparator or reference method result.  
 
Difference (D) for reference result < threshold  glucose:  
ùë´=ùë¥‚àíùë™ 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 22 of 42 13.5.2  Primary objective :  
The threshold glucose value is 100 mg/dL  (5.55 mmol/L).  Accuracy will be assessed using the 
CLSI. Point -of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved 
Guideline ‚Äì Third Edition . CLSI document POCT12 -A3. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2013.  
i.e.,  D within ¬±12 mg/dL ( ¬±0.67 mmol/L)  for comparator result < 100 mg/dL  (5.55 mmol/L)   and 
RD within ¬±12.5%  for comparator result ‚â• 100  mg/dL (5.55 mmol/L) . 
For RD, the percent of results within  ¬±5%,  ¬±10%,  ¬±12.5%,  ¬±15% and  ¬±20% will be computed.  
For D, the percent less than or equal to ¬±5 mg/dL  (¬±0.28mmol /L), ¬±10 mg/dL  (¬±0.56 mmol /L), 
¬±12.0 mg/dL  (¬±0.67 mmol/L) , ¬±15 mg/dL  (¬±0.83 mmol/L) , and ¬±20 mg/dL  (¬±1.11 mmol/L)  will 
be computed.  
The RD and D distribution tables will be constructed using a threshold of 100 mg/dL (5.55 mmol/L) .  
As discussed in section 13.1 (Sample Size),  with n =240, the critical number (minimum) of 
accurate results is 228, which yields approximately 95% chance of satisfying the criterion if the 
actual probability that any result will be accurate is at least  96.77%. Symbolically, this criterion 
is equivalent  to tes ting the  hypothesis:  
 
H0 : Prob{accurate}< 96.77% versus  the alternative:  
H1  :  Prob{accurate } ‚â•   96.77%  
This test has a power of about 95%, with n =240, to reject H 0 if the actual probability of obtaining 
an accurate result is 96.77%. Conversely, there is about a 95% chance that the null will NOT be 
rejected if the actual probability that a result with the evaluation device would satisfy this definition 
of accuracy is only about   92.03%.  
13.5.[ADDRESS_734683] 98% of the n = [ADDRESS_734684] fall 
within ¬±15 mg/dL (¬±0.83 mmol/L)  of the comparator result (comparator < 75 mg/dL /4.16 mmol/L )) 
or ¬±20% of the comparator result (comparator ‚â• 75 mg/dL /4.16 mmol/L ).  Thus, with n = 240, 
there must be at least 236 BGMS results satisfying this requirement.  This is equivalent to testing 
the hypotheses:  
H0: Prob{accurate}< 98.33% versus  the alternative:  
H1:        Prob{accurate } ‚â•   98.33%  
There is approximately a 95% chance of rejecting H0 in favor of H1 if the actual probability that a 
meter measurement would satisfy the ¬±15mg/dL or 20% is 98.33%.  Conversely, there is about a 
95% chance that the null will NOT be rejected if the actual probability that a result with the 
evaluation device would satisfy this definition of accuracy is only about   96.23%.   It is possible 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 23 of 42 that the sample size after the study is completed may not be exactly 240.  The critical values will 
be approximately 95% or 98% of results (first and second parts of primary objective, respectively), 
and the associated hypotheses will be adjusted to reflec t the change while maintaining no more 
than a 95% chance of rejecting the null hypotheses.  
13.6 Neonates < 24 hrs. old and Neonates in NICU  ‚Äì Other Objectives  
In addition to the neonates less than 28 days of age, additional analyses of data from neonatal 
subjects ‚â§ [ADDRESS_734685] the laboratory instrument results (modified Bland -
Altman plot).  
13.6.[ADDRESS_734686] 5 subjects <[ADDRESS_734687] any or all subjects in common.  
13.7 Hematocrit Analysis ‚Äì Other Objectives  
13.7.[ADDRESS_734688] 
hematocrit.  
13.8 Bilirubin Analysis ‚Äì Other Objectives   
For neonates who would have bilirubin results, regression analysis will be used to assess the effects 
of bilirubin on the difference between meter and laboratory reference method blood glucose 
measurements.  
There must be at least [ADDRESS_734689] deviation, minimum and maximum room temperature, and humidity will 
be computed.  
13.10  Data Evaluability  
Blood glucose data will be considered not evaluable for the following reasons:  
‚Ä¢ Samples with no associated or valid hematocrit value.  
‚Ä¢ Samples with no associated or valid Cobas 6000  value.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 24 of 42 ‚Ä¢ Failure to begin to separate the plasma from the red cells within [ADDRESS_734690].  
‚Ä¢ The collected samples exceed a maximum of 5 h of sample withdrawal time, and 
will be kept at room temperature  (23 ¬± 5 ¬∞C) before evaluation.  
‚Ä¢ For a given sample, the meter is missing a replicate.  
‚Ä¢ Results of the g lucose analyzer blood sample  are not within ¬±4% of each other, 
100* (Rep2 -Rep1)/Rep1, or ¬±4mg/dL  (0.22mmol/L)  of each other (Rep2 -Rep1) 
if the average falls below 100mg/dL  (5.5mmol/L) . 
14.[ADDRESS_734691]/sample. The unique number will be entered on 
the CRFs. The site will create a procedure to de -identify subjects from samples so that the 
staff members documenting subject names will not have access to sample resul ts and the 
staff members testing the samples will not have access to subject names. A master list of 
subject names,  with their subject  IDs, will be kept by [CONTACT_559231].  
14.2 Study personnel will complete and sign all appropriate forms in compliance with GCP. 
CRFs should be completed legibly, in black or blue ink. If it is necessary to make 
corrections, a single line should be drawn through the original entry, the new entry is written 
in, and the correction initialed and dated by [CONTACT_559232].  
14.3 Study  data will be primarily collected through an electronic data capture ( EDC ) system 
used by [CONTACT_127007]. The d ata will be recorded on forms by [CONTACT_559233]. All source forms will be 
retained by [CONTACT_779].  
14.4 In addition to data collection, the EDC system will be used for data cleaning as well as 
monitoring operations. Site users will be trained on this system before the start of the study 
and their access to EDC system will be contingent upon successful comple tion of training 
requirements.    
15.0 Amendments to the Protocol  
15.1 Any change to this protocol requires a protocol amendment (or revision) unless the IRB 
agrees to an administrative change (for minor changes).  
15.2 Determine the justification(s) for the protocol revision, impact of the changes on subject 
safety, the clinical or statistical significance of the data, impact of changes on the clinical 
investigators and their staff, and impact on timely completion of the  clinical trial.  
15.3 Determine if the revision meets the criteria of a Substantial Amendment .  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734692] of the clinical trial may arise from changes 
to the protocol or from new information relating to the scientific documents in 
support of the trial. Substantial changes require notification to the overseeing IRB 
before implementation. For any questions on whether a change would be considered 
substantial, consult with the respective IRB.  
15.4.2  Amendments to the trial are regarded as ‚Äúsubstantial‚Äù where they are likely to have 
a significant impact on the:  
‚Ä¢ Safety, health or rights or physical or mental integrity of the subjects , 
‚Ä¢ Scientific value of the trial including robustness or reliability of the data 
generated by [CONTACT_1758] , 
‚Ä¢ Conduct or management of the trial , 
‚Ä¢ Quality or safety of any investigational product used in the tria l. 
15.4.3  An amendment is only to be regarded as ‚Äúsubstantial‚Äù when one or more of the above 
criteria are met but the IRB  may have additional requirements that shall be 
considered.  
15.4.4  Examples of substantial amendments may include (but are not limited to):  
‚Ä¢ New tests  
‚Ä¢ Increase in the number of visits due to safety issues associated with the 
ongoing trial  
‚Ä¢ Change of inclusion/exclusion criteria  
‚Ä¢ Change in the number of participants  
‚Ä¢ Updated PI  
‚Ä¢ Informed Consent Form (ICF)  
‚Ä¢ Updated investigator brochure with relevant safety information  
‚Ä¢ Change in the management of the study  
‚Ä¢ Temporary halt to the study or restart of the trial after a temporary halt  
15.5 Once justified, the protocol changes can be drafted and the changes documented in the 
Revision History. The changes are to be incorporated directly into the body of the protocol 
document itself (revised protocol).  
15.6 Once the drafted revision is approved internally and by [CONTACT_978], it will be submit ted to the 
IRB, where required. All subsequent, IRB -approved, revised protocols would be numbered 
sequentially.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734693] assure that each investigator (and his/her staff) is following the most 
recent IRB approved amendment or revised protocol as the study proceeds. The sponsor  
must ensure that the study monitors, investigator(s) and study staff have been trained with 
respect to any recent protocol amendments and revisions prior to implementation.  
16.0 Deviations from the clinical protocol  
16.1 A protocol deviation is any alteration or modification to the procedures described in the 
protocol. The investigator is not allowed to deviate from the protocol. The only exceptions 
to this are:  
16.1.[ADDRESS_734694]'s rights, safety and well -being, or 
the scientific integrity of the clinical investigation without prior approval of the 
sponsor and IRB.  
16.1.2  Prospective deviations that broaden the scope of the protocol (waivers of the 
protocol) are prohibited.   Under emergency circumstances, these instances can 
proceed.  
16.2 Procedures for recording, reporting and analyzing protocol deviations  will include 
recording  the deviation on a Protocol Deviation log form to be supplied by [CONTACT_1034] . 
17.0 Device Accountability  
17.1 Description of the procedures for the accountability of investigational devices as follows:  
17.1.1  Access to investigational devices shall be controlled and the investigational devices 
shall be used only in the clinical investigation and according to the protocol.  
17.1.2  The sponsor shall keep records to document the physical location of all 
investigational devices from shipment of investigational devices to the investigation 
sites until return or disposal.  
17.1.3  Accountability: The PI [INVESTIGATOR_1660] a delegate shall keep records documenting the receipt, use, 
return and disposal of the investigational devices, (including unused, expi[INVESTIGATOR_559223]) , which shall include:  
‚Ä¢ Date of receipt  
‚Ä¢ Identification of each device (serial number of meter or strip lot)  
‚Ä¢ The expi[INVESTIGATOR_5695], if applicable  
‚Ä¢ Date(s) of use  
‚Ä¢ Subject number  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 27 of 42 ‚Ä¢ Date of return of unused, expi[INVESTIGATOR_559224], if applicable  
18.0 Regulatory  
Ascensia (sponsor) has determined that according to IDE requirements of 21 CFR 812.2(c), this 
IVD study meets all conditions for IDE exemption and therefore submission of an IDE application 
to FDA is not required.  Determination is based on the following:  
The Contour Next and Contour Plus Elite Glucose Monitoring Systems (IVDs);  
‚Ä¢ are labeled in accordance with 21 CFR 809.10(c)  
‚Ä¢ are non -invasive  
‚Ä¢ do not require an invasive sampling procedure that presents significant risk  
‚Ä¢ do not by [CONTACT_33901] a subject  
‚Ä¢ are not used as a diagnostic procedure without confirmation of the diagnosis by [CONTACT_20904], 
medically established diagnostic product or procedure . 
 
18.[ADDRESS_734695] safety. The IRB will determine if 
the Informed Consent is required according to local regulations and requirements or 
if consent is not required  (ISO [ZIP_CODE]:2019(E)) .  
18.1.2  The investigational site may not begin the study until the IRB has given its written 
and dated approval via a letter that identifies the version/date of the protocol and 
ICF, if applicable , or a notification  that consent is not required .  
18.1.[ADDRESS_734696] be provided to the Investigator and to sponsor 
prior to the SIV. 
18.2 Study  Documentation Procedures  
18.2.1  The investigator will keep study records for a minimum of three years. Alternatively, 
other arrangements may be made with Ascensia for study document storage.  
18.2.2  Study Investigational Devices  will be labeled " For Investigational Use only . The 
performance characteristics of this product have not been established " for this study.  
18.2.3  After study  completion , all BGMS s will be disinfected before they are returned to 
Ascensia. A decontamination log will be completed for the used meters. The meters, 
unused strip vials, control solutions, and meter UGs will be accounted for at the site 
and returned to the Ascensia Study Ma nager upon completion of the trial.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 28 of 42 18.3 Investigator's Report of Study Closure  
18.3.[ADDRESS_734697] disposition 
and other study details, as appropriate, to the Study Manager and the IRB.  This 
report will be completed within 3 months of the study closure date.   
18.3.3  In addition, the Study Manager, or designee, will report the completion of the study 
to the IRB within 6 months of study closure.  
19.0 Statements of compliance  
19.1 This clinical investigation will be conducted in compliance with applicable requirements : 
19.1.1  Protection of Human Subjects regulations in 21 CFR part 50 . 
19.1.2  IRB regulations in 21 CFR part 56 . 
19.1.3  Investigational Device Exemptions regulations in 21 CFR part 812 . 
19.1.4  Declaration  of Helsinki . 
19.1.5  CLSI. Point -of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; 
Approved Guideline ‚Äì Third Edition . CLSI document POCT12 -A3. Wayne, PA: 
Clinical and Laboratory Standards Institute; 2013.  
19.1.6  International Standards: ISO20916:2019(E) ‚Äì In vitro diagnostic medical devices ‚Äì 
Clinical performance studies using specimens from human subjects ‚Äì Good Study 
Practice and In Vitro Diagnostic Regulation 2017/[ADDRESS_734698] BS EN [ZIP_CODE]:2002, ‚ÄúPerformance evaluation of in vitro diagnostic 
medical devices .‚Äù 
19.[ADDRESS_734699] been obtained.  
19.3 Clinical trial insurance shall be provided as appropriate.  
20.0 Informed Consent Process  
The IRB will  determine if the Informed Consent is required according to local regulations and 
requirements for use of residual blood samples for this study.   
 
The following will only apply if Informed Consent is required by [CONTACT_1201].  If the IRB determines 
that consent is not required , this section will not apply.  
 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734700] ‚Äôs parent/guardian - Legally Authorized 
Representative (LAR)  - will complete the informed consent process before performing any 
study procedures.  
20.2 The LAR  will be informed about the study objectives, investigational devices, study 
procedures, expected study duration, and risks of study participation.  
20.3 Study participation is voluntary. The information will be given in written form (ICF) as 
well as verbally by [CONTACT_093].  
20.[ADDRESS_734701] ‚Äôs LAR will sign and date the ICF.  The ICF will then be dated and signed by 
[CONTACT_093].  
20.[ADDRESS_734702] ‚Äôs LAR will receive 
a copy of the ICF and if applicable, insurance terms and conditions.  
21.0 Adverse events  and adverse device effects  
The procedures to be performed under this protocol are considered to be of low risk since the 
glucose testing procedures will use residual samples which are remnants of neonatal  blood 
collected as part of routine prescribed practice.  
Due to the nature of this study, no adverse events (AE) are expected as per the following:  
21.1 This study only includes residual ( ‚Äòleft-over‚Äô) samples of blood collected by [CONTACT_38183], 
approved technique for prescribed tests.  
21.2 No neonate will be exposed to any of the BGMS at any point; all study activities will be 
conducted in the institution‚Äôs lab.  
21.[ADDRESS_734703] that the nursing staff overseeing the 
babies will not be informed of any study results , and samples will be de -identified prior to 
being given to the laboratory staff who perform study testing    
21.4 Regardless  of the above, any experience that the investigator considers to be an A E will be 
documented and reported immediately to Ascensia . 
21.5 Definition of Adverse Events  
21.5.1  Adverse Event (AE):  Adverse event refers to any untoward medical occurrence, 
inappropriate patient management decision, unintended disease or injury, or 
untoward clinical signs in subjects, users, or other persons, with any connection to 
to study related activities, whether or not related to the IVD medical device under 
investigation.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734704]  (ADE or Adverse Effect): Any AE resulting from insufficient 
or inadequate instructions for use, installation, operation, or any malfunction of the 
IVD medical Device under investigation.  This i ncludes any AE resulting from use 
error or from unintentional misuse of the device.  
21.5.3  Serious Adverse Event (SAE): Refers to an AE that led to any of the following:   
a) death,  
b) serious deterioration in the health of the subject, users or other persons as defined 
by [CONTACT_10980]:  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function including 
chronic diseases, or  
3) in-patient or prolonged hospi[INVESTIGATOR_11956], or  
4) medical or surgical intervention to prevent life -threatening illness or injury or 
permanent  impairment to a body structure or a body function,  
c)   fetal distress, fetal death , or a congenital abnormality or birth defect , including 
physical or mental impairment.  
 
21.5.[ADDRESS_734705]  (SADE):  Adverse device effect that has resulted in 
any of the consequences of an SAE.                            
 
21.6 Adverse Event Classification  
Table 3. Classification of Adverse Event s (ISO [ZIP_CODE]: 2019)  
Adverse Events  Non -device related  Device related  
 Applies to :  
‚Ä¢ Interventional Studies  
‚Ä¢ Sampling procedure causes 
direct harm to the subject  Applies to :  
‚Ä¢ Interventional Studies: inaccurate test result leads 
to indirect harm to the subject.  
‚Ä¢ Sampling procedure causes direct harm to the 
subject  
 
Non-Serious  Adverse event (includes all 
categories)  Adverse device effect  
Serious  Serious Adverse event (includes 
all categories that are serious)  Serious adverse device effect  
Anticipated  Unanticipated  
Anticipated Serious 
adverse device 
effect  Unanticipated 
Serious adverse 
device effect  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page 31 of 42 21.7 Adverse Event Reporting  
21.7.1  AEs will be documented during this study by [CONTACT_559234].  The 
Investigator or designee will sign and date an AE Form for each AE that is observed.   
21.7.2  AEs will be evaluated by a member of the study staff and the PI.  The nature of each 
event and date of onset, outcome, course, maximum intensity and action taken for 
treatment should be established. Details of any corrective treatment should be 
recorded on  the AE Form.  
21.7.3  Investigators should follow up on the status of any AE until the event has been 
resolved, or until the condition has stabilized.  
21.7.4  The Investigator or designee will notify the Study Manager or  Study Monitor within 
24 hours of any S AE that occurred during the study.  Ascensia will promptly review 
all information relevant to the safety of the investigational device . 
21.7.5  Upon the receipt of a report of an SAE by [CONTACT_559235], the report will be immediately forwarded to:  
Rimma Shaginian, MD, MPH  
Medical Lead , Emerging Markets  
Global Medical Affairs, Ascensia Diabetes Care  
Email: [EMAIL_10659]  
22.[ADDRESS_734706] led to a SADE.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734707].  
24.0 Suspension /Premature termination  and Subject Withdrawal Criteria  
24.[ADDRESS_734708] ‚Äôs sample may be withdrawn from the study at the discretion of the Investigator.   
25.[ADDRESS_734709] be reviewed and approved in writing by [CONTACT_559236]. The sponsor‚Äôs intention is neithe r to influence nor to prevent the publication of 
the study results to the medical and scientific community. The review is exclusively aimed 
at protecting the sponsor's proprietary information existi ng either at the date of 
commencement of the study or generated during the study. Details of the publication policy 
and related sponsor and princip al investigator responsibilities are included in the clinical 
investigation agreement.  
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734710] the Ascensia Study Manager at  the telephone number listed below.  
Maria Teresa Viggiani  
Phone (Office): [ADDRESS_734711]: 914 -417-9310  
E-mail: [EMAIL_10656]                    OR Rosanna Cirio  
Phone (Office): [ADDRESS_734712]: 914 -343-5736  
E-mail: [EMAIL_10657]  
28.0 Bibliograph y   
1. Adamkin DH. Postnatal glucose homeostasis in late -preterm and term infants. Pediatrics  2011; 
127: 575 ‚Äì79. 
2. British Association of Perinatal Medicine. Identification and management of neonatal 
hypocycaemia in the full term infant. A BAPM framework for practice. 2017. 
https://www.bapm.org/resources/40 -identification -and-management -of-
neonatalhypoglycaemia -in-the-full-term-infant -2017 (accessed  Sept 23, 2020).  
3. CLSI. Point -of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved 
Guideline  ‚Äì Third Edition . CLSI document POCT 12 ‚ÄìA3. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2013.  
4. Draper, N.R.  and Smith, H. (1998) . Applied Regression Analysis , 3rd Ed., John Wiley and Sons, 
NY. 
5. Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as 
at risk. J Pediatr . 2012;161:787 -791.   
6. ISO [ZIP_CODE]: 2013. In vitro diagnostic test systems -requirements for blood glucose monitoring 
systems for self -testing in managing diabetes mellitus. Reference number ISO: 2013(E), 
Geneva: International Organization for Standardization; 2013.  
7. ISO 2 0916 : 201 9. In vitro diagnostic medical devices ‚Äîclinical performance studies using 
specimens fro human subjects ‚ÄîGood Study Practice . Geneva: International Organization for 
Standardization (ISO); 201 9. 
8. ISO [ZIP_CODE]: 2016. Point -of-care testing (POCT) ‚Äîrequirements for quality and competence. 
Geneva: International Organization for Standardization (ISO); 2016.  
9. Lucas A, Morley R, Cole TJ. Adverse neurodevelopmental outcome of moderate neonatal 
hypoglycaemia. BMJ 1988;297:1304 ‚Äì8. 
10. Movalia MK, Ogino MT. Point of care glucose testing in neonatal hypoglycemia. Point Care . 
2006;5:95 ‚Äì9. 
11. Nuntnarumit P, Chittamma A, Pongmee P, Tangnoo A, Goonthon S. Clinical performance of 
the new glucometer in the nursery and  neonatal intensive care unit. Pediatr Int . 2011;53:218 ‚Äì
23. 
12. Roth -Kleiner M, Stadelmann Diaw C, Urfer J, Ruffieux C, Werner D. Evaluation of different 
POCT devices for glucose measurement in a clinical neonatal setting. Eur J Pediatr . 
2010;169:1387 ‚Äì95.  
13. Rozance PJ, Hay WW. Hypoglycemia in newborn infants: features associated with adverse 
outcomes. Biol Neonate . 2006;90:74 -86. 
Protocol /CIP: GCA -PRO -2021 -003-01 - Amendment 1      Ascensia Diabetes Ca re 
Version : 14Oct2022         CONFIDENTIAL  
  
Page [ADDRESS_734713] meters according to the UG  instructions for HCPs . 
Health Care Professionals  
Health care professionals or persons using this system on multiple patients should follow the 
infection control procedure and the recommendations for prevention of blood -borne transmissible 
diseases approved by [CONTACT_559237] . 
 
The following disinfection solutions are recommended : 70% isopropyl alcohol, 6.0% sodium 
hypochlorite (full bleach) ,  0.6% sodium hypochlorite (diluted bleach), 
didecyldimethylammonium chloride (DDAC) . 
 
NOTE:    Using cleaning and disinfecting solutions other than  those recommended by [CONTACT_559238].   The cleaning and disinfecting 
directions provided should not  cause any damage or degradation to the external case, buttons,  or 
display.  
 
CAUTION : Do not allow any solution  to run into the meter through open areas, such as around 
the buttons or the meters test strip or data ports, such as USB port.   
Blood glucose meters must be cleaned and disinfected by [CONTACT_559239] . 
 
References  
Protection of laboratory workers from occupationally acquired infections; approved guideline ‚Äì 
third edition.  CLSI document M29 -A3.  ISBN1 -[ZIP_CODE] -567-4. 
Rutala W, Weber D . Healthcare Infection Control Practices Advisory Committee.  Guideline for 
disinfection and sterilization in healthcare facilities, 2008.  C enters for Disease Control and 
Prevention . 
Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 35 of 42 
 Appendix B  - Instructions for Processing of Blood for the glucose analyzer  
 
Processing of Neonatal  Blood for laboratory glucose  analysis  
Once collected, process the microtainer tube for laboratory glucose analysis as follows:   
‚Ä¢ Label all tubes with the subject number using a Sharpie¬Æ-like marker.   
‚Ä¢ Gently invert the microtainer tube several times to mix the anticoagulant.  
‚Ä¢ Centrifuge the whole blood immediately to separate the plasma from the red blood cells.  The 
centrifugation start time must occur within [ADDRESS_734714].  The timing 
of all meter testing/centrifugation will be recorded on the appropriate CRF.   
‚Ä¢ It is recommended that after centrifugation, the plasma is transferred from the microtainer tube 
to a small clean tube or container with a cap.   Ensure the tube is labeled and the cap is secured , 
and proceed  with the site‚Äôs laboratory glucose analyzer procedures .  
‚Ä¢ The plasma will be tested in duplicate with the laboratory analyzer within [ADDRESS_734715], plasma samples may be 
refrigerated .  
‚Ä¢ Insufficient (or suspected to be insufficient) samples, missing samples, and other sample issues 
should be recorded in the CRF and on the glucose analyzer  printout , as appropriate.  If a sample 
is hemolyzed, record it in the CRF.   
 
Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 36 of 42 
 Appendix C - Instructions for Tracking Accuracy and Precision of the 
Laboratory Glucose Analyzer  
Procedure for Tracking Accuracy and Precision of Site Laboratory Analyzer  
Performance of the Cobas 6000  will be assessed to ensure accuracy.  Analyzer performance will 
be tracked by [CONTACT_392577]: the Laboratory Analyzer QC procedure regularly applied by [CONTACT_42042] , and the testing of serum controls provided by [CONTACT_127007] . 
The following are the procedures required for each method:  
I. Laboratory Analyzer QC Procedure  
The Cobas 6000  will be maintained and operated according to the instructions in the 
manufacturer‚Äôs operating manual by [CONTACT_779]‚Äôs lab specifications/SOP previously reviewed by [CONTACT_360936]. 
Before the study begins, the analyzer will be set up and the appropriate maintenance will be 
performed.  
The site will perform glucose analyzer control tests in accordance with the site ‚Äôs quality control 
check  procedures and requirements.  Site staff will keep a log for the analyzer, including daily 
operational checks and maintenance.  
II. Ascensia Serum Controls1 
A set of three  serum control levels will be provided to the investigator to document the 
performance of the Cobas [ADDRESS_734716] been assayed by a 
method traceable to one proposed for use as a national glucose reference method.  
Serum Control Testing Schedule:  
‚Ä¢ Pre-study: The controls will be assayed (singlet readings) on the  Laboratory Analyzer for 
at least three runs prior to the assay of subject samples. The runs will occur over at least 
three days, if possible.  The data will be sent to the Ascensia Study Ma nager, or designee, 
for review before the study begins.  
‚Ä¢ Once the study begins, serum control testing should be completed on each Analyzer on the 
Monday and Friday of the first week , and then on one day for each week that the study 
continues.   
‚Ä¢ Record all data on the CRF.  One reading will be recorded for each control level (for a total 
of 3 readings per run).   
 
 
1 Caution: The serum glucose traceability controls are human serum -based and must be handled using universal 
precautions.  
Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 37 of 42 
  
Proper Handling of Ascensia Serum Controls  
Ascensia  completed the characterization of serum controls purchased from Bio -Techne¬Æ (formerly 
Bionostics). During the characterization, staff observed that sample stratification during thawing 
can occur if the control vials are not handled judiciously. The recommended procedure is as 
follows.  
‚Ä¢ Store the frozen controls in a -20C freezer upon arrival.  
‚Ä¢ Thaw the frozen control amber glass vials at 2 -8¬∫C for 2 -3 days in the refrigerator.  Each 
vial holds approximately 2.0 mL.  
‚Ä¢ Before opening, mix the vials well by [CONTACT_559240] 10 times.  
‚Ä¢ Prepare an aliquot of each level in capped microcentrifuge tubes.  Cap tightly.  We prefer 
Fisherbrand‚Ñ¢ Microcentrifuge 0.5mL tubes (PN 02 -681-333) with O -ring seal caps (PN 
02-681-358).  
‚Ä¢ Store any remaining control in the amber glass vials at 2 -8¬∫C. 
‚Ä¢ Before running a control sample on the laboratory analyzer, mix the aliquot tubes by [CONTACT_559241].  
‚Ä¢ At the beginning of each day, remix the amber glass vials and refill the aliquot tubes.  When 
not in use, store the aliquots at 2 -8¬∫C. 
‚Ä¢ The thawed control use life is two weeks.  Discard all thawed control ‚Äîaliquot tubes and 
amber glass vials ‚Äîafter two weeks.  
‚Ä¢ Since slow thawing for 2 -3 days is recommended, it is advisable to keep an extra thawed 
set available for testing.  
 
  
Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page [ADDRESS_734717] tube was not adequate 
for measurement , or is broken.     
‚Ä¢ Ensure the tube setting on the Hemata Stat II ‚Ñ¢ is set to 0.5 mm ID (inner diameter ). 
‚Ä¢ Samples collected from residual capi[INVESTIGATOR_17276] (heel -stick) will be collected in treated 
micro -hematocrit tubes.     
2. Place a microhematocrit tube against the surface of the blood drop.  
3. Fill the microhematocrit tube about halfway.  Do not over -fill.  Then immediately place one of 
the microhematocrit tube openings in the clay sealant.  Press into the clay [ADDRESS_734718] the sealed microhematocrit tube into the Hematastat II ‚Ñ¢ micro -centrifuge.  Note: it is 
very important to place the microhematocrit tube in centrifuge rotor with clay side down .  
Balance the rotor with another hematocrit tube containing  water.  
5. Click run to s pin for the preset 60 seconds.   
6. Measure hematocrit using the Hematastat reader or other hematocrit reader approved by [CONTACT_103].  
7. Summary of Instructions for the Hematastat reader : 
‚Ä¢ After collection and centrifugation of hematocrit, place tube in the reader  slot, with clay 
side to the left.  Press enter to read.  
‚Ä¢ Slide the marker on the reader to the exact line where the clay and red blood cells meet.  
Press enter to ‚Äúenter  interface : sealant/RBCs.‚Äù    
‚Ä¢ Then move the marker to the exact line where the red blood cells meet the plasma . Press 
enter to ‚Äúenter interface: RBCs/plasma.‚Äù   
‚Ä¢ Slide the marker to the exact line where the plasma  ends. Press enter to ‚Äúenter interface: 
plasma/air.‚Äù  
‚Ä¢ The result in the display is the hematocrit percentage for that sample.  
8. Record hematocrit result on the appropriate form.  
  
Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 39 of 42 
 Attachment 1 - CONTOUR  NEXT  User Guide  
 
 
 
 

Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 40 of 42 
   

Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 41 of 42 
 Attachment  2 - CONTOUR  PLUS ELITE  User Guide  
 
 
 
 

Protocol /CIP: GCA -PRO -2021 -003-01 ‚Äì Amendment 1      Ascensia Diabetes Ca re 
Version :14Oct2022         CONFIDENTIAL   
Page 42 of 42 
  
 
 
